{"id":"61b0a5580f6e","type":"article","url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","title":"BETAMI-DANBLOCK is representatief: bètablokker-effect ook geldig in echte Noorse infarct-populatie","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","huisarts"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag348","source_url":"https://doi.org/10.1093/eurheartj/ehag348","authors":["Anna Meta Dyrvig Kristensen","Jarle Jortveit","Therese Holmager","Dan Atar","Michael Hecht Olsen","Arnhild Bakken","Terje Steigen","Henrik Schirmer","Thor Edvardsen","Alf Inge Larsen","Jan Erik Otterstad","Eva Prescott","John Munkhaugen","Sigrun Halvorsen"],"significance":6,"published":"2026-06-02","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/"],"congress":"","summary_en":"Comparison of participants in the BETAMI (n=2,867) and DANBLOCK (n=2,707) trials with the Norwegian nationwide myocardial infarction registry (NORMI, n=20,804) — all patients with recent MI, LVEF ≥40% and no heart failure. NORMI patients were older on average (66 vs 63 years) and had more diabetes, prior coronary disease and LVEF 40-49%. Absolute 3-year risks were higher in NORMI (mortality/MI 12.0%) than in the trials (7.7-7.8%). A transportability analysis (reweighting the trial population to NORMI characteristics) showed that the beta-blocker treatment effect remained consistent. BETAMI-DANBLOCK findings therefore generalise to the broader Norwegian — and by extension European — post-MI population.","created":"2026-07-03T10:32:59Z","updated":"2026-07-03T13:31:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Vergelijking van de deelnemers in de BETAMI- (n=2.867) en DANBLOCK-studies (n=2.707) met de Noorse landelijke infarctregistratie NORMI (n=20.804) — alle patiënten met recent infarct, LVEF ≥40% en zonder hartfalen. De NORMI-patiënten waren gemiddeld ouder (66 versus 63 jaar) en hadden vaker diabetes, eerdere coronaire ziekte en LVEF 40-49%. De absolute 3-jaars risico's waren hoger in NORMI (mortaliteit/MI 12,0%) dan in de trials (7,7-7,8%). Een transportabiliteitsanalyse (waarbij de trial-populatie werd geherweegd naar de NORMI-karakteristieken) liet zien dat het behandeleffect van bètablokkers consistent bleef. De BETAMI-DANBLOCK-bevindingen zijn dus generaliseerbaar naar de bredere Noorse — en daarmee Europese — infarct-populatie.","abstract_original":"BACKGROUND AND AIMS: In patients with myocardial infarction (MI), no heart failure, and left ventricular ejection fraction (LVEF) ≥ 40%, the combined BETAMI-DANBLOCK trial showed that beta-blockers reduced the risk of all-cause mortality or major adverse cardiovascular events. This study evaluated the representativeness of the trial. METHODS: Participants in BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with a cohort of revascularized MI patients with LVEF ≥40%, and no heart failure from the Norwegian Myocardial Infarction Registry (the NORMI cohort)(n = 20 804). Baseline characteristics were evaluated, and absolute risks of all-cause mortality and/or MI were estimated. A transportability analysis was conducted by weighting the BETAMI-DANBLOCK population according to the NORMI cohort. RESULTS: Median age was 66 years (interquartile range [IQR]: 57-74) in the NORMI cohort and 63 years (IQR: 55-70) in BETAMI and DANBLOCK. Patients in the NORMI cohort had a higher prevalence of diabetes, previous coronary artery disease, and LVEF 40-49%, compared with trial participants. At 3-year follow-up, the absolute risk of all-cause mortality or MI was 12.0% in the NORMI cohort, 7.7% in BETAMI, and 7.8% in DANBLOCK. Corresponding risks of MI were 6.3%, 5.6%, and 4.3%, respectively. The treatment effects of beta-blockers were similar when the trial population was weighted according to the characteristics of the NORMI cohort. CONCLUSIONS: Compared with the NORMI cohort, participants in BETAMI and DANBLOCK were younger, had a lower proportion of certain comorbidities, and experienced a lower risk of all-cause mortality and MI. Despite these differences, the effect of beta-blockers remained consistent when the trial population was weighted according to the NORMI cohort."}